A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE
THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND MAJOR
ADVERSE KIDNEY EVENTS IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN OR EQUAL TO 27 KG/M2 AND ATHEROSCLEROTIC
CARDIOVASCULAR DISEASE AND/OR CHRONIC KIDNEY DISEASE
- Registry ID
- J1I-MC-GZBO
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- ELI LILLY CANADA INC
- Start date
- 2025-04-29
- Last update
- 2024-04-04
Conditions
- CARDIOVASCULAR DISEASE
- CHRONIC KIDNEY DISEASE (CKD)
Related clinical trials
- A PHASE IIB, RANDOMISED, MULTICENTRE, DOUBLE-BLIND STUDY TO EVALUATE THE EFFECT OF BAXDROSTAT IN COMBINATION WITH DAPAGLIFLOZIN COMPARED WITH BAXDROSTAT ON ALBUMINURIA IN PARTICIPANTS WITH CHRONIC KIDNEY DISEASE AND HIGH BLOOD PRESSURE
- ZENITH: A PHASE 3 GLOBAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
TO EVALUATE THE EFFICACY AND SAFETY OF ZILEBESIRAN IN ADDITION TO STANDARD OF CARE
IN REDUCING MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULT PATIENTS WITH
HYPERTENSION NOT ADEQUATELY CONTROLLED AND WITH EITHER ESTABLISHED
CARDIOVASCULAR DISEASE OR HIGH RISK FOR CARDIOVASCULAR DISEASE
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY
TO INVESTIGATE THE EFFECT OF ORFORGLIPRON ON THE INCIDENCE OF MAJOR ADVERSE
CARDIOVASCULAR EVENTS IN PARTICIPANTS WITH ESTABLISHED ATHEROSCLEROTIC
CARDIOVASCULAR DISEASE AND/OR CHRONIC KIDNEY DISEASE (ATTAIN-OUTCOMES)
- A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL WITH AN OPEN-LABEL EXTENSION
TO ASSESS THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF EMPAGLIFLOZIN TABLETS IN
PAEDIATRIC PATIENTS WITH CHRONIC KIDNEY DISEASE (EMPA-KIDNEY® KIDS)
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE
THE EFFECT OF MUVALAPLIN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR
EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE HAD A PRIOR
ATHEROSCLEROTIC CARDIOVASCULAR EVENT OR ARE AT RISK FOR A FIRST ATHEROSCLEROTIC
CARDIOVASCULAR EVENT ¿ MOVE-LP(A)
- A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE
THE IMPACT OF MARIDEBART CAFRAGLUTIDE ON CARDIOVASCULAR OUTCOMES IN
PARTICIPANTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OVERWEIGHT OR
OBESITY (MARITIME-CV)
View on source registry